Influence of COVID-19 on Clinical Outcomes of Clostridioides difficile Infection
Antibiotics · 18.08.2026 · 15 (8) · 806
DOI: 10.3390/antibiotics15080806 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 18.08.2026. Verfasst von Martin Novotny und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Rastislavova 43, 04190 Kosice, Slovakia. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Slovak Republic, Ministry of Education, Research, Development and Youth of the Slovak Republic.
Abstract (Originalsprache)
Backgroud/Objectives: Clostridioides difficile infection (CDI) remains a major problem for healthcare facilities. The COVID-19 pandemic was associated with increased hospitalizations, frequent antibiotic use, and changes in infection prevention and control regulations, which may have influenced the epidemiological and clinical characteristics of CDI. The aim of this study was to evaluate whether a history of COVID-19 was associated with clinical characteristics, treatment exposure, recurrence, ribotype distribution, and mortality in patients with CDI.
Methods
This retrospective study included patients diagnosed with CDI during the period 2020–2022 at the Louis Pasteur University Hospital in Košice, Slovakia. We analyzed 324 patients, of whom 172 (53.1%) had no history of COVID-19 and 144 (44.4%) had previous or concurrent COVID-19, defined as documented infection within three months before or at the time of CDI diagnosis. Eight patients (2.5%) developed COVID-19 after CDI diagnosis and were excluded from the comparative analyses.
Results
Patients with previous or concurrent COVID-19 had higher exposure to PPIs (88.2% vs. 73.3%; p = 0.0009), corticosteroids (70.1% vs. 26.2%; p < 0.0001), cephalosporins (72.9% vs. 61.6%; p = 0.034) and macrolides (37.5% vs. 20.3%; p = 0.0007). Overall antibiotic exposure was high (93.8%) and did not differ significantly between patients with previous or concurrent COVID-19 and those without COVID-19 (93.8% vs. 94.2%; p = 0.871). Previous or concurrent COVID-19 was not associated with increased 90-day mortality after CDI (42.4% vs. 43.6%; p = 0.824).
Conclusions
Our findings suggest that a history of COVID-19 was associated with the risk factor profile, recurrence rate and the molecular epidemiology of CDI, rather than with a more severe clinical course or worse prognosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Rastislavova 43, 04190 Kosice, Slovakia.
- Department of Medical and Clinical Microbiology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Trieda SNP 1, 04011 Kosice, Slovakia.
- Department of Paediatrics and Adolescent Medicine, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Trieda SNP 1, 04011 Kosice, Slovakia.
ORCID-Profile: Daniela Javorska, Katarina Curova
Förderung
- Ministry of Health of the Slovak Republic
- Ministry of Education, Research, Development and Youth of the Slovak Republic
Zitieren
APA
Novotny, M., Javorska, D., Toporova, A., Kardos, N., & Curova, K. (2026). Influence of COVID-19 on Clinical Outcomes of Clostridioides difficile Infection. Antibiotics, 15(8), 806. https://doi.org/10.3390/antibiotics15080806
Vancouver
Novotny M, Javorska D, Toporova A, Kardos N, Curova K. Influence of COVID-19 on Clinical Outcomes of Clostridioides difficile Infection. Antibiotics. 2026;15(8):806. doi:10.3390/antibiotics15080806
BibTeX
@article{Novotny2026,
author = {Novotny, Martin and Javorska, Daniela and Toporova, Annamaria and Kardos, Nicolas and Curova, Katarina},
title = {Influence of COVID-19 on Clinical Outcomes of Clostridioides difficile Infection},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {8},
pages = {806},
doi = {10.3390/antibiotics15080806}
}
EUVIMED